par Duffaud, F;van der Burg, Maria;Namer, Moïse;Vergote, Ignace;Willemse PHB, B;ten Bokkel Huinink, Wim;Guastalla, Jean Paul;Nooij, j;Kerbrat, Pierre;Piccart-Gebhart, Martine
;Tumolo, Salvatore;Favalli, Giuseppe;van der Vange, N;Lacave, Ángel Jiménez;Wils, J;Splinter, Ted;Einhorn, N;Roozendaal, K J;Rosso, Riccardo;Vermorken, Jan Baptist
Référence Anti-cancer drugs, 12, 2, page (159-162)
Publication Publié, 2001-02

Référence Anti-cancer drugs, 12, 2, page (159-162)
Publication Publié, 2001-02
Article révisé par les pairs
Titre: |
|
Auteur: | Duffaud, F; van der Burg, Maria; Namer, Moïse; Vergote, Ignace; Willemse PHB, B; ten Bokkel Huinink, Wim; Guastalla, Jean Paul; Nooij, j; Kerbrat, Pierre; Piccart-Gebhart, Martine; Tumolo, Salvatore; Favalli, Giuseppe; van der Vange, N; Lacave, Ángel Jiménez; Wils, J; Splinter, Ted; Einhorn, N; Roozendaal, K J; Rosso, Riccardo; Vermorken, Jan Baptist |
Informations sur la publication: | Anti-cancer drugs, 12, 2, page (159-162) |
Statut de publication: | Publié, 2001-02 |
Sujet CREF: | Sciences bio-médicales et agricoles |
MeSH keywords: | Adult |
Aged | |
Aged, 80 and over | |
Antineoplastic Agents, Hormonal -- therapeutic use | |
Carcinoma -- drug therapy | |
Carcinoma -- mortality | |
Drug Evaluation | |
Drug Resistance | |
Female | |
Humans | |
Middle Aged | |
Neoplasm Staging | |
Ovarian Neoplasms -- drug therapy | |
Ovarian Neoplasms -- mortality | |
Platinum Compounds -- therapeutic use | |
Salvage Therapy | |
Survival Rate | |
Treatment Outcome | |
Triptorelin -- therapeutic use | |
Note générale: | Clinical Trial |
Evaluation Studies | |
Journal Article | |
Multicenter Study | |
Langue: | Anglais |
Identificateurs: | urn:issn:0959-4973 |
info:doi/10.1097/00001813-200102000-00010 | |
info:scp/0035090073 | |
info:pmid/11261890 |